International journal of clinical pharmacology research
-
Int J Clin Pharmacol Res · Jan 2001
Randomized Controlled Trial Multicenter Study Clinical TrialShort-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.
We investigated the efficacy and tolerability of short-term treatment with tropisetron, a selective, competitive 5-HT3-receptor antagonist in fibromyalgia. The trial was designed as a prospective, multicenter, double-blind, parallel-group, dose-finding study. We randomly assigned 418 patients suffering from primary fibromyalgia to receive either placebo, 5 mg, 10 mg or 15 mg tropisetron once daily for 10 days. ⋯ The safety and tolerability of tropisetron was good; gastrointestinal tract symptoms were the most frequently reported adverse events. Short-term treatment of fibromyalgia patients with 5 mg tropisetron for 10 days proved to be efficacious and well tolerated. In this study a bell-shaped dose-response curve was seen.
-
Sodium channel blockers have been reported to be effective in relieving neuropathic pain. However, although intravenous lidocaine has proved to be effective, in some patients oral mexiletine fails to produce adequate pain relief. In this study, we investigated the analgesic effect of flecainide, a long-lasting antitachyarrhythmic drug, on postherpetic neuralgia. ⋯ The patients were assessed using a 100 mm visual analog scale 1 month after treatment. Significant improvement compared with the pretreatment reading was found. This study suggests that the action of flecainide in blocking the sodium channel is potent and long-lasting and that, like the intravenous formulation, the oral formulation has a stable analgesic effect on postherpetic neuralgia.
-
Int J Clin Pharmacol Res · Jan 2001
Lack of antagonism between nicorandil and sulfonylurea in stable angina pectoris.
The aim of this study was to clarify whether or not nicorandil (a potassium channel opener) caused adverse reactions in patients with angina pectoris who also had diabetes mellitus treated with sulfonylurea (a potassium channel inhibitor). Nineteen diabetic patients with angina pectoris were enrolled, eight were treated with glibenclamide (group A) and 11 were not (group B). ⋯ Exercise tolerance, frequency of anginal attacks and diabetes mellitus control were not perturbed by treatment in either group. In conclusion, there were no antagonistic reactions from the combination of nicorandil with sulfonylurea in angina pectoris complicated by diabetes mellitus.